Recent data on individuals living with overweight and obesity treated with the GLP-1R/GCGR co-agonist SAR425899 indicated that such individuals exhibit a smaller-than-expected decrease in the sleeping metabolic rate, increased fat oxidation but no overt induction of energy expenditure [152]. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.